Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quantitation of Hepatic Mitochondrial Fluxes in T2D Patients With NAFLD Treated With Pioglitazone
NCT05305287Phase 4Recruiting
- Sponsor
- UT Health San Antonio
- Start
- Nov 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pioglitazone in non-alcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), sponsored by UT Health San Antonio. Started Nov 2022; status: recruiting.
02
Drugs
pioglitazone
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05305287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305287.